Takeda Pharmaceutical Company Limited Stock NYSE
Stocks
TAK
US8740602052
Pharmaceuticals
OTC Markets Traded|
Market Closed -
NYSE
07:00:03 27/10/26 am AEDT
|
5-day change | 1st Jan Change | ||
| 20.43 USD | +0.94% |
|
+4.18% | +31.05% |
| 26/10 | Takeda Pharmaceutical Eyes 2027 Japan Filing for Gastric Cancer Treatment | MT |
| 26/10 | Takeda to seek Japan approval for gastric cancer drug next year | RE |
| Market Cap | 10,302B 65.39B 58.47B 54.09B 48.98B 91.67B 6,221B 93.17B 651B 257B 3,254B 245B 240B | P/E 2027 * |
51.1x | P/E 2028 * | 32.4x |
|---|---|---|---|---|---|
| Enterprise Value | 14,210B 90.19B 80.64B 74.61B 67.55B 126B 8,580B 129B 898B 355B 4,488B 338B 331B | EV / Sales 2027 * |
3.02x | EV / Sales 2028 * | 2.92x |
| Free-Float |
99.18% | Yield 2027 * |
3.17% | Yield 2028 * | 3.23% |
| Markets | Quality | ||
|---|---|---|---|
NYSE
| TAK | Delayed | |
CBOE
| TAK | Real-time | |
|
London S.E.
| 0A87 | Delayed | |
|
Mexican S.E.
| TAK N | End-of-day quote | |
|
Tradegate
| TKDA | Real-time | |
|
Deutsche Boerse AG
| TKDA | Delayed | |
|
Börse Stuttgart
| TKDA | Delayed | |
|
Boerse Muenchen
| TKDA | Real-time |
Last Transcript: Takeda Pharmaceutical Company Limited
| 1 day | +0.94% | ||
| 1 week | +4.18% | ||
| Current month | +12.31% | ||
| 1 month | +8.32% | ||
| 3 months | +18.50% | ||
| 6 months | +22.85% | ||
| Current year | +31.05% |
| 1 week | 19.9 |  | 20.55 |
| 1 month | 17.75 | | 20.55 |
| Current year | 14.84 | | 20.55 |
| 1 year | 12.99 | | 20.55 |
| 3 years | 12.58 | | 20.55 |
| 5 years | 12.28 | | 20.55 |
| 10 years | 12.28 | | 31.29 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 01/01/2025 | |
Mikuno Furuta
DFI | Director of Finance/CFO | 48 | 01/04/2024 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 48 | 01/02/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Andrew Plump
BRD | Director/Board Member | 61 | 01/06/2015 |
Steven Gillis
BRD | Director/Board Member | 73 | 01/01/2019 |
Mikuno Furuta
BRD | Director/Board Member | 48 | 01/06/2024 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.94% | +4.18% | - | - | 65.39B | |
| +0.45% | +3.13% | +54.96% | +125.16% | 1,140B | |
| +0.94% | +4.93% | +39.86% | +78.72% | 641B | |
| +0.39% | +1.44% | +25.77% | +97.48% | 507B | |
| +0.06% | +1.54% | +48.06% | +66.52% | 383B | |
| -3.21% | -2.10% | +60.72% | +33.22% | 347B | |
| +1.73% | +2.39% | +25.55% | +54.63% | 293B | |
| +0.09% | +1.89% | +2.47% | +26.99% | 266B | |
| +1.22% | +4.63% | +52.40% | +64.85% | 240B | |
| +1.70% | +3.67% | +31.21% | +102.15% | 197B | |
| Average | +0.39% | +2.92% | +37.89% | +72.19% | 445.98B | |
| Weighted average by Cap. | -0.03% | +2.98% | +41.76% | +84.31% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 4,702B 29.84B 26.68B 24.69B 22.35B 41.84B 2,839B 42.52B 297B 118B 1,485B 112B 110B | 4,796B 30.44B 27.22B 25.18B 22.8B 42.67B 2,896B 43.37B 303B 120B 1,515B 114B 112B |
| Net income | 196B 1.25B 1.11B 1.03B 933M 1.75B 119B 1.78B 12.41B 4.91B 62.01B 4.68B 4.58B | 323B 2.05B 1.83B 1.7B 1.54B 2.87B 195B 2.92B 20.41B 8.07B 102B 7.69B 7.53B |
| Net Debt | 3,907B 24.8B 22.18B 20.52B 18.58B 34.77B 2,359B 35.34B 247B 97.66B 1,234B 93.08B 91.09B | 3,705B 23.51B 21.03B 19.45B 17.61B 32.96B 2,237B 33.5B 234B 92.59B 1,170B 88.25B 86.37B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/10/26 | USD 20.43 | +0.94% | 2,367,366 |
| 23/10/26 | USD 20.24 | -0.59% | 2,099,212 |
| 22/10/26 | USD 20.36 | +2.16% | 3,461,934 |
| 21/10/26 | USD 19.93 | -0.75% | 1,671,406 |
| 20/10/26 | USD 20.08 | +2.40% | 2,907,340 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4502 Stock
- TAK Stock
Select your edition
All financial news and data tailored to specific country editions
